An FDA advisory panel of
experts will vote tomorrow on whether to recommend that the agency approve the pill. The drug has stirred a debate over what constitutes a normal range of sexual desire among women.
"This is a real disease," says Dr. Peter J. Piliero, Boehringer's director of medical affairs in the U.S. "There's an unmet medical need among premenopausal women to have a treatment." Many experts say that sexually dysfunction in women is much harder to diagnose than in men. Critics contend the company is overstating the prevalence of the condition, which could cause anxiety in some women.
advertisement
advertisement